Loewenstein G, Sah S, Cain DM.
The Unintended Consequences of Conflict
of Interest Disclosure.
JAMA: The Journal of the American Medical
Association 2012;307:669-70 Abstract
Beitrag im Forum Gesundheitspolitik Link
14. März 2012
29. Februar 2012
Avastin bei metastasiertem Brustkrebs - Zulassungsbehörden entscheiden gegensätzlich
Identische Datenlage - entgegengesetzte Entscheidungen.
Dazu ein Beitrag im Forum Gesundheitspolitik Link
Die amerikanische Zulassungsbehörde FDA hat ein transparentes Verfahren von Anhörung und Entscheidung. Die Anhörunegn stehen als Video und als Transkript (28./29.6.2011: 581 Seiten) Verfügung Link
Die Europäische Zulassungsbehörde EMA lässt sich hingegen bei ihrer Entscheidung nicht in die Karten schauen.nicht.
6 der 12 Mitglieder der Scientific Advisory Group on Oncology der EMA haben Interessenkonflikte.
In der Sendung von Monitor am 1.3. um 21 Uhr im ARD wird dieses Thema aufgegriffen. Link
16. Februar 2012
"Tamiflu III": Warum ein Review auf Daten von 68% der durchgeführten Studien zum Grippe-Blockbuster verzichten muss?
Beitrag im Forum Gesundheitspolitik Link
Es werde Licht - Transparenzregelungen in den USA werden konkretisiert
Beitrag im Forum Gesundheitspolitik Link
Seelsorge für die Industrie. SPIEGEL 16.5.2011
Seelsorge für die Industrie
Von Jörg Blech
Link
(versehentlich im Mai nicht veröffentlicht, aber immer noch lesenswert)
Being the Ghost in the Machine: A Medical Ghostwriter's Personal View
PLoS 9.8.2011
Link
Introduction Top
Ethical concerns about medical ghostwriting have been directed primarily at “guest” authors and the pharmaceutical companies that pay them. One voice that is largely missing is that of the ghostwriters themselves who, after all, create the documents that are in the ethical and legal crosshairs. Without them, one could argue, there can be no fraud, because it is they who create the fraudulent product.
For almost 11 years, I worked as a medical writer, creating a variety of pieces including the occasional ghostwritten article. For the most part, I never saw the finished paper, nor did I care to. This article describes what I did, why I did it, why I stopped doing it, and what I think might be done about the problem of fraud in authorship.
(versehentlich im August nicht veröffentlicht, aber immer noch lesenswert)
Link
Introduction Top
Ethical concerns about medical ghostwriting have been directed primarily at “guest” authors and the pharmaceutical companies that pay them. One voice that is largely missing is that of the ghostwriters themselves who, after all, create the documents that are in the ethical and legal crosshairs. Without them, one could argue, there can be no fraud, because it is they who create the fraudulent product.
For almost 11 years, I worked as a medical writer, creating a variety of pieces including the occasional ghostwritten article. For the most part, I never saw the finished paper, nor did I care to. This article describes what I did, why I did it, why I stopped doing it, and what I think might be done about the problem of fraud in authorship.
(versehentlich im August nicht veröffentlicht, aber immer noch lesenswert)
13. Oktober 2011
Leitlinien zu Diabetes und Cholesterin: 52% der Autoren mit Interessenkonflikten
3. September 2011
PLoS Medicine. Beiträge zu Ghost Writing, Aug. 2011
Gegen ghost writing. Die Herkunft von Studien offen legen - schwierig aber notwendig
in Forum Gesundheitspolitik
in Forum Gesundheitspolitik
10. August 2011
Being the Ghost in the Machine: A Medical Ghostwriter's Personal View
PLoS 9.8.2011
Link
Introduction
Ethical concerns about medical ghostwriting have been directed primarily at “guest” authors and the pharmaceutical companies that pay them. One voice that is largely missing is that of the ghostwriters themselves who, after all, create the documents that are in the ethical and legal crosshairs. Without them, one could argue, there can be no fraud, because it is they who create the fraudulent product.
For almost 11 years, I worked as a medical writer, creating a variety of pieces including the occasional ghostwritten article. For the most part, I never saw the finished paper, nor did I care to. This article describes what I did, why I did it, why I stopped doing it, and what I think might be done about the problem of fraud in authorship.
Link
Introduction
Ethical concerns about medical ghostwriting have been directed primarily at “guest” authors and the pharmaceutical companies that pay them. One voice that is largely missing is that of the ghostwriters themselves who, after all, create the documents that are in the ethical and legal crosshairs. Without them, one could argue, there can be no fraud, because it is they who create the fraudulent product.
For almost 11 years, I worked as a medical writer, creating a variety of pieces including the occasional ghostwritten article. For the most part, I never saw the finished paper, nor did I care to. This article describes what I did, why I did it, why I stopped doing it, and what I think might be done about the problem of fraud in authorship.
Abonnieren
Posts (Atom)
Posts
